Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.
暂无分享，去创建一个
A. El-Khoueiry | S. Choo | J. Neely | M. Tschaika | T. Meyer | S. Soleymani | T. Welling | B. Sangro | M. Kudo | J. Yao | I. Melero | C. Hsu | T. Yau | Y. Kang | T-Y. Kim | J. Trojan | W. Yeo | A. Chopra